MedWatch

Kåre Schultz after guidance hike: Hard to gauge generic competition

The US competitor to Lundbeck’s epilepsy drug Sabril is long in coming and this is partly the reason behind the new guidance hike for the Danish company. In the first half year of 2017, Sabril continued to gain market shares in the US.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Dansk biotekboss rejser 91 mio til at udfordre Novo Nordisk

Et amerikansk biotekselskab, som er grundlagt af en dansk molekylærbiolog, har rejst 91 mio. kr. til at fremme programmer inden for diabetes, fedme og fedtlever, herunder et "transformativt" diabeteslægemiddel rettet mod biologiske mål, som Novo Nordisk også arbejder med.

Related articles